Free Trial

Penumbra (PEN) Competitors

Penumbra logo
$234.24 -2.17 (-0.92%)
Closing price 03:59 PM Eastern
Extended Trading
$232.35 -1.89 (-0.81%)
As of 05:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PEN vs. LNTH, ITGR, GEHC, PHG, ZBH, SOLV, SNN, STVN, GKOS, and BLCO

Should you be buying Penumbra stock or one of its competitors? The main competitors of Penumbra include Lantheus (LNTH), Integer (ITGR), GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), Solventum (SOLV), Smith & Nephew SNATS (SNN), Stevanato Group (STVN), Glaukos (GKOS), and Bausch + Lomb (BLCO). These companies are all part of the "medical" sector.

Penumbra vs. Its Competitors

Lantheus (NASDAQ:LNTH) and Penumbra (NYSE:PEN) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

In the previous week, Lantheus had 1 more articles in the media than Penumbra. MarketBeat recorded 9 mentions for Lantheus and 8 mentions for Penumbra. Lantheus' average media sentiment score of 1.70 beat Penumbra's score of 0.58 indicating that Lantheus is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lantheus
6 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Penumbra
5 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Lantheus has a beta of 0.12, suggesting that its share price is 88% less volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500.

Lantheus has higher revenue and earnings than Penumbra. Lantheus is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lantheus$1.53B3.36$312.44M$3.5221.14
Penumbra$1.19B7.59$14.01M$1.06220.98

Lantheus has a net margin of 16.55% compared to Penumbra's net margin of 3.41%. Lantheus' return on equity of 36.99% beat Penumbra's return on equity.

Company Net Margins Return on Equity Return on Assets
Lantheus16.55% 36.99% 20.55%
Penumbra 3.41%11.14%8.40%

Lantheus currently has a consensus price target of $131.20, suggesting a potential upside of 76.32%. Penumbra has a consensus price target of $305.07, suggesting a potential upside of 30.24%. Given Lantheus' stronger consensus rating and higher probable upside, equities research analysts clearly believe Lantheus is more favorable than Penumbra.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lantheus
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Penumbra
0 Sell rating(s)
3 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.88

99.1% of Lantheus shares are held by institutional investors. Comparatively, 88.9% of Penumbra shares are held by institutional investors. 2.0% of Lantheus shares are held by company insiders. Comparatively, 5.0% of Penumbra shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Lantheus beats Penumbra on 11 of the 17 factors compared between the two stocks.

Get Penumbra News Delivered to You Automatically

Sign up to receive the latest news and ratings for PEN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PEN vs. The Competition

MetricPenumbraMED INSTRUMENTS IndustryMedical SectorNYSE Exchange
Market Cap$9.07B$6.67B$5.57B$20.65B
Dividend YieldN/A1.20%4.23%3.65%
P/E Ratio220.9825.4928.6127.29
Price / Sales7.5987.71411.3153.19
Price / Cash82.9120.3636.0222.28
Price / Book7.814.668.234.60
Net Income$14.01M$174.76M$3.23B$995.22M
7 Day Performance-4.02%-1.13%-0.01%-0.80%
1 Month Performance-10.13%1.22%5.60%3.55%
1 Year Performance19.03%2.58%26.54%7.35%

Penumbra Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PEN
Penumbra
4.7335 of 5 stars
$234.24
-0.9%
$305.07
+30.2%
+23.4%$9.07B$1.19B220.984,500
LNTH
Lantheus
4.6257 of 5 stars
$79.19
-1.5%
$130.50
+64.8%
-34.0%$5.48B$1.53B22.50700Positive News
Gap Down
ITGR
Integer
3.1759 of 5 stars
$117.05
-3.3%
$145.00
+23.9%
-2.0%$4.08B$1.72B55.4711,000News Coverage
Positive News
GEHC
GE HealthCare Technologies
4.1262 of 5 stars
$74.61
-1.9%
$88.27
+18.3%
-7.2%$34.16B$19.67B15.7153,000Positive News
Analyst Forecast
PHG
Koninklijke Philips
2.9768 of 5 stars
$23.84
-1.4%
N/A-7.3%$22.96B$19.50B55.4466,678
ZBH
Zimmer Biomet
4.9506 of 5 stars
$92.58
-1.2%
$111.33
+20.3%
-11.8%$18.32B$7.68B20.4817,000News Coverage
Analyst Upgrade
SOLV
Solventum
0.7277 of 5 stars
$76.24
-2.9%
$81.50
+6.9%
+52.8%$13.19B$8.25B35.3022,000Analyst Upgrade
SNN
Smith & Nephew SNATS
2.8855 of 5 stars
$29.95
-1.1%
$28.00
-6.5%
+5.9%$13.12B$5.81B13.8717,349Positive News
STVN
Stevanato Group
N/A€24.23
-1.5%
N/A+21.0%€7.34B€1.19B47.515,521Positive News
GKOS
Glaukos
4.3346 of 5 stars
$101.69
-1.7%
$134.67
+32.4%
-20.2%$5.81B$383.48M-42.91780Analyst Forecast
BLCO
Bausch + Lomb
3.0202 of 5 stars
$13.83
-0.4%
$15.54
+12.4%
-13.4%$4.89B$4.83B-13.4313,500

Related Companies and Tools


This page (NYSE:PEN) was last updated on 7/16/2025 by MarketBeat.com Staff
From Our Partners